These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 28058376)

  • 1. Parkinsonism secondary to duloxetine use: a case report.
    Bayrak A; Cetin B; Meteris H; Kesebir S
    North Clin Istanb; 2015; 2(3):243-246. PubMed ID: 28058376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development.
    Montgomery S
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 2():5-11. PubMed ID: 24921676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders.
    Baldwin DS
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 2():12-5. PubMed ID: 24921677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.
    Fava GA; Benasi G; Lucente M; Offidani E; Cosci F; Guidi J
    Psychother Psychosom; 2018; 87(4):195-203. PubMed ID: 30016772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of serotonin-noradrenaline reuptake inhibitor duloxetine on the intervertebral disk-related radiculopathy in rats.
    Handa J; Sekiguchi M; Krupkova O; Konno S
    Eur Spine J; 2016 Mar; 25(3):877-87. PubMed ID: 26394856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential efficacy of serotonin noradrenaline reuptake inhibitor duloxetine in dropped head syndrome: A case report and review of the literature.
    Funao H; Isogai N; Ishii K
    Heliyon; 2020 Aug; 6(8):e04774. PubMed ID: 32885085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syndrome of inappropriate antidiuretic hormone secretion: a story of duloxetine-induced hyponatraemia.
    Amoako AO; Brown C; Riley T
    BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25911354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probable Association of an Attack of Bilateral Acute Angle-Closure Glaucoma With Duloxetine.
    Shifera AS; Leoncavallo A; Sherwood M
    Ann Pharmacother; 2014 Jul; 48(7):936-939. PubMed ID: 24732786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin syndrome triggered by postoperative administration of serotonin noradrenaline reuptake inhibitor (SNRI).
    Takata J; Arashi T; Abe A; Arai S; Haruyama N
    JA Clin Rep; 2019 Aug; 5(1):55. PubMed ID: 32025920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medication of the month. Duloxetine (Cymbalta)].
    Pitchot W
    Rev Med Liege; 2006 Nov; 61(11):787-90. PubMed ID: 17191749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant.
    Keks NA; Hope J; Keogh S; Copolov DL
    Australas Psychiatry; 2018 Oct; 26(5):537-540. PubMed ID: 30198305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential inhibition of cardiac and neuronal Na(+) channels by the selective serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine.
    Stoetzer C; Papenberg B; Doll T; Völker M; Heineke J; Stoetzer M; Wegner F; Leffler A
    Eur J Pharmacol; 2016 Jul; 783():1-10. PubMed ID: 27130441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of duloxetine in medico-legal death investigations in Victoria, Australia (2009-2012).
    Pilgrim JL; Gerostamoulos D; Drummer OH
    Forensic Sci Int; 2014 Jan; 234():165-73. PubMed ID: 24378318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
    Iyengar S; Webster AA; Hemrick-Luecke SK; Xu JY; Simmons RM
    J Pharmacol Exp Ther; 2004 Nov; 311(2):576-84. PubMed ID: 15254142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
    Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
    J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor.
    Fan QY; Xue R; Li Y; Zhang TT; He XH; Fan SY; Li YF; Zhong BH; Zhang YZ; Li J
    CNS Neurosci Ther; 2016 Aug; 22(8):700-6. PubMed ID: 27207183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute dystonia after using single dose duloxetine: case report.
    Karakaş Uğurlu G; Onen S; Bayındırlı D; Cayköylü A
    Psychiatry Investig; 2013 Mar; 10(1):95-7. PubMed ID: 23483133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample.
    Irene R; Luis MA; Helena DC; David P; Ramon DJ; Inmaculada G
    Int J Psychiatry Clin Pract; 2009; 13(2):100-8. PubMed ID: 24916728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
    Novick D; Montgomery W; Haro JM; Moneta MV; Zhu G; Yue L; Hong J; Dueñas H; Brugnoli R
    Neuropsychiatr Dis Treat; 2016; 12():383-92. PubMed ID: 26966361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.